Insulin Overpricing Litigation
Large employers across the United States—including corporations, cities, counties, school boards, universities, and labor unions—are now stepping forward to pursue justice in a growing wave of litigation surrounding insulin overpricing. These organizations, which often self-fund employee healthcare plans, have borne the brunt of dramatic and unjustified insulin price increases.
If your organization has suffered financial losses due to inflated insulin costs, Mass Torts & Environmental Law Firm, LLC, LLC can help. Call us today at (803) 247-3388 for a free case evaluation.
Understanding the Insulin Overpricing Scheme
Insulin manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, in collaboration with Pharmacy Benefit Managers (PBMs) such as CVS Caremark, Express Scripts, and OptumRx, are accused of engaging in a complex pricing scheme. This scheme allegedly revolved around rebate agreements that incentivized PBMs to favor high-priced insulin products in exchange for substantial rebates.
As a result, insulin costs in the United States are approximately four times higher than they should be, placing a significant financial burden on large employers and public institutions. These inflated prices were passed on through healthcare plans, leading to multi-million dollar losses over time.






